EMERGENT BIOSOLUTIONS INC

Insider buying at Emergent BioSolutions signals management confidence amid a 50% stock decline and regulatory scrutiny. Learn how this impacts risk and upside for investors.

Insightful insider sales: Paul Anthony Williams’ 3,000‑share Rule 144 drop for Emergent Biosolutions shows routine trading amid rising sell‑pressure.

Emergent BioSolutions’ insider buying surge signals management’s confidence as the stock climbs toward its 52‑week high, highlighting a promising shift in strategy and value potential.

Emergent BioSolutions CFO sells shares, buys options—insider moves that hint at a cautious yet confident outlook amid price volatility.

Explore how CFO Lindaahl Richard S.’s recent insider trades reveal a careful cash‑management shift at Emergent BioSolutions, balancing liquidity with long‑term upside.

Emergent BioSolutions insider buy: New director John D. Fowler Jr. snaps up 5,006 shares at $8.99, hinting at upside amid rising buzz and potential pipeline gains.

Emergent BioSolutions insider selling sparks debate: CFO’s recent stock sales may hint at confidence shifts, yet core biothreat business remains steady.